The estimated Net Worth of Steven T Thornton is at least $1.8 Million dollars as of 15 June 2007. Steven Thornton owns over 10,000 units of Halozyme Therapeutics stock worth over $1,484,750 and over the last 17 years Steven sold HALO stock worth over $314,700.
Steven has made over 2 trades of the Halozyme Therapeutics stock since 2007, according to the Form 4 filled with the SEC. Most recently Steven exercised 10,000 units of HALO stock worth $28,000 on 15 June 2007.
The largest trade Steven's ever made was selling 30,000 units of Halozyme Therapeutics stock on 21 May 2007 worth over $314,700. On average, Steven trades about 13,333 units every 8 days since 2007. As of 15 June 2007 Steven still owns at least 25,000 units of Halozyme Therapeutics stock.
You can see the complete history of Steven Thornton stock trades at the bottom of the page.
Steven's mailing address filed with the SEC is C/O HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO, CA, 92121.
Over the last 17 years, insiders at Halozyme Therapeutics have traded over $92,345,799 worth of Halozyme Therapeutics stock and bought 9,720,772 units worth $67,958,365 . The most active insiders traders include Randal J Kirk, David A Ramsay, and Gregory Ian Frost. On average, Halozyme Therapeutics executives and independent directors trade stock every 21 days with the average trade being worth of $3,961,432. The most recent stock trade was executed by Michael J. La Barre on 27 August 2024, trading 5,580 units of HALO stock currently worth $102,728.
we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
Halozyme Therapeutics executives and other stock owners filed with the SEC include: